Attrition‐Enhanced Deracemization of the Antimalaria Drug Mefloquine | Zendy

Engwerda Anthonius H. J. | Zendy; Maassen Rick | Zendy; Tinnemans Paul | Zendy; Meekes Hugo | Zendy; Rutjes Floris P. J. T. | Zendy; Vlieg Elias | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Premium

Attrition‐Enhanced Deracemization of the Antimalaria Drug Mefloquine

Author(s) -

Engwerda Anthonius H. J.,

Maassen Rick,

Tinnemans Paul,

Meekes Hugo,

Rutjes Floris P. J. T.,

Vlieg Elias

Publication year - 2019

Publication title -

angewandte chemie international edition

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 5.831

H-Index - 550

eISSN - 1521-3773

pISSN - 1433-7851

DOI - 10.1002/anie.201811289

Subject(s) - mefloquine , enantiomer , drug , malaria , pharmacology , racemic mixture , chemistry , combinatorial chemistry , plasmodium falciparum , stereochemistry , medicine , immunology

Mefloquine is an important drug for prevention and treatment of malaria. It is commercially available as a racemic mixture, wherein only one enantiomer is active against malaria, while the other one causes severe psychotropic effects. By converting the drug into a compound that crystallizes as a racemizable racemic conglomerate, the deracemization of mefloquine into the desired enantiomer was achieved.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here

Accelerating Research